Herceptin can cause side effects. Some of these side effects may be serious and may lead to hospitalisation or death. Not all side effects reported for Herceptin are included in this leaflet. Should your general health worsen or if you experience any untoward effects while taking Herceptin, please consult your doctor, pharmacist or healthcare professional for advice.
Herceptin administration can result in severe hypersensitivity reactions (including anaphylaxis), infusion reactions and pulmonary (lung/respiratory) events. These may cause death. In most cases, these symptoms occurred during or within 24 hours of administration of Herceptin. During a Herceptin infusion, chills, fever and other flu-like symptoms may occur. These are very common. They mainly occur with the first infusion and are temporary. Other infusion-related symptoms are: feeling sick (nausea), vomiting, pain, increased muscle tension and shaking, headache, dizziness, breathing difficulties, wheezing, high or low blood pressure, heart rhythm disturbances (palpitations, heart fluttering or irregular heart beat), swelling of the face and lips, rash and feeling tired. These symptoms can be serious and some patients have died (see “Warnings and precautions”).
You should tell your doctor immediately if you notice:
- breathlessness (including breathlessness at night)
- cough
- swelling of the lips, face or throat
- palpitations (hear fluttering or irregular heart beat)
- fluid retention (swelling) in the legs or arms or
Heart problems can occur and are serious. They include weakening of the heart muscle possibly leading to heart problems, and heart rhythm disturbances. Your doctor will monitor your heart regularly during treatment. Taking Herceptin can result in serious and potentially deadly lung problems, including:
- A severe shortness of breath
- Too little oxygen in the body
- Weakening of the heart valve between the heart and the lungs
- Swelling of the lungs
- Fluid in or around the lungs
- Scarring of the lungs
Problems like these may occur after an infusion of Herceptin. Some effects mainly occur with the first infusion and during the first few hours after the start of the infusion. Occasionally, symptoms start later than six hours after the infusion begins. Sometimes, symptoms may improve and then get worse later. If either of these happens to you, contact your doctor immediately.
Frequent side effects of Herceptin are: swelling of the face and lips, wheezing, heart rhythm disturbances, diarrhea, weakness, skin rashes, chest pain, abdominal pain, joint pain, muscle pain, allergic reactions, itchiness, abnormal blood counts (anemia, low platelet count and low white blood count), dry mouth and skin, constipation, dry watery eyes, heart burn (dyspepsia), sweating, infections including bladder and skin infections, feeling weak and unwell, shingles, anxiety, inflammation of the breast, depression, inflammation of the pancreas or liver, abnormal thinking, kidney disorder, dizziness, increased muscle tone/tension (hypertonia), loss of appetite, tremor, weight loss, numbness or tingling of the fingers and toes, altered taste, nail disorders, asthma, hair loss, lung disorders, inability to sleep (insomnia), back pain, sleepiness (somnolence), neck pain, nose bleed, bone pain, bruising, acne, hemorrhoids, leg cramps, hand-foot syndrome (palms of hands or soles of feet tingle, become numb, painful, swollen or red), arthritis, blood pressure changes, anaphylactic reactions, loss of eyelashes, failure of lungs to develop, the womb, abnormal kidney.
If you notice any side effects not mentioned in this leaflet, please inform your doctor or pharmacist.
Reporting of side effects
If you get side effects, talk to your doctor or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects to SAHPRA via the “6.04 Adverse Drug Reaction Reporting Form”, found online under SAHPRA’s publications: https://www.sahpra.org.za/Publications/Index/8: By reporting side effects, you can help provide more information on the safety of Herceptin.